CA75103L1013
© Globe Newswire
10.12.2025
RKV
LISTED
TSX
Rakovina Therapeutics Announces Upcoming Webinar with Variational AI
News Preview
From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer Therapies From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer Therapies...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
RKV
LISTED
TSX
Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update
News Preview
All dollar amounts reflected in Canadian dollars unless otherwise stated....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.11.2025
RKV
LISTED
TSX
Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program
News Preview
VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, announces that further to its news release dated June 30, 2025, and in accordance with the terms of a debenture in...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
24.11.2025
RKV
LISTED
TSX
Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting
News Preview
Data highlights progress in Rakovina’s AI-derived PARP-1 inhibitor program Data highlights progress in Rakovina’s AI-derived PARP-1 inhibitor program...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
24.11.2025
RKV
LISTED
TSX
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
News Preview
Variational AI’s Enki™ generative AI platform designed novel ATR/mTOR dual inhibitors with brain penetrance and activity in PTEN-deficient tumor models Variational AI’s Enki™ generative AI platform designed novel ATR/mTOR dual inhibitors with brain penetrance and activity in PTEN-deficient tumor models...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2025
RKV
LISTED
TSX
Rakovina Therapeutics’ President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit
News Preview
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that its President and Chief Scientific Officer, Prof. Mads Daugaard, has been invited to present...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
RKV
LISTED
TSX
Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
News Preview
VANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that new data will be presented in two posters at the Society for Neuro-Oncology (SNO) Annual Meet...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.10.2025
RKV
LISTED
TSX
Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference
News Preview
VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) is pleased to announce the successful presentation of new data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 23–27 in Boston, Massachusetts. The...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2025
RKV
LISTED
TSX
Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference
News Preview
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV, FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that new preclinical data from its ATR inhibitor program will be presented in a poster session at...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
RKV
LISTED
TSX
Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced that Executive Chairman, Jeffrey Bacha, and Chief Financial Officer, Dr. David Kideckel, will a...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2025
RKV
LISTED
TSX
Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update
News Preview
All dollar amounts reflected in Canadian dollars unless otherwise stated All dollar amounts reflected in Canadian dollars unless otherwise stated...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2025
RKV
LISTED
TSX
Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis
News Preview
VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced that Chief Scientific Officer Dr. Mads Daugaard has been invited to present this week at the 13t...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
12.08.2025
RKV
LISTED
TSX
Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
News Preview
KT-3283, a dual PARP-HDAC inhibitor, to serve as first development program in NanoPalm’s strategic expansion into the oncology field KT-3283, a dual PARP-HDAC inhibitor, to serve as first development program in NanoPalm’s strategic expansion into the oncology field...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2025
RKV
LISTED
TSX
Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre
News Preview
VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, is pleased to highlight its long-standing collaboration with the University of British Columbia (UBC) and its af...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2025
RKV
LISTED
TSX
Rakovina Therapeutics Announces Stock Option Grants
News Preview
VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (FSE: 7JO0) (the “Company” or “Rakovina”), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that its board of directors has approved the grant of an aggrega...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.07.2025
RKV
LISTED
TSX
Rakovina Therapeutics Announces Warrant Exercise Incentive Program
News Preview
VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company” or “Rakovina”) a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery is pleased to announced that, as an update to the previously announced warrant amendments, the Compan...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.07.2025
RKV
LISTED
TSX
Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening
News Preview
Compounds developed through collaboration with Variational AI show targeted activity Compounds developed through collaboration with Variational AI show targeted activity...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.07.2025
RKV
LISTED
TSX
Rakovina Therapeutics Granted DTC Eligibility to Expand U.S. Investor Access
News Preview
VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that its shares are now eligible for electronic...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2025
RKV
LISTED
TSX
Rakovina Therapeutics Congratulates Partner - Variational AI for Winning LifeSciencesBC’s 2025 Emerging Biotech Company of the Year Award
News Preview
Award Recognition underscores the importance of AI-driven drug discovery Award Recognition underscores the importance of AI-driven drug discovery...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.07.2025
RKV
LISTED
TSX
Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development
News Preview
VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to highlight the strength and scientific leadership of its...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2025
RKV
LISTED
TSX
Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants
News Preview
VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”) announces that it will apply to the TSX Venture Exchange (the “Exchange”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
RKV
LISTED
TSX
Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025
News Preview
VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
RKV
LISTED
TSX
Rakovina Therapeutics Announces Results from 2025 Annual General Meeting
News Preview
VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery is pleased to announce the results of voting at its 2025 annual general...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2025
RKV
LISTED
TSX
Rakovina Therapeutics Announces Share Consolidation Effective Date
News Preview
VANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE:7JO) (“Rakovina” or the “Company”) is pleased to announce that the effective date for the previously announced share consolidation (the “Consolidation”) will be June 24, 2025. As outlined in the Company’s news release dated May 15, 2025, th...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2025
RKV
LISTED
TSX
Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million
News Preview
VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the closing of its previously announced non-brokered...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
RKV
LISTED
TSX
Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update
News Preview
All dollar amounts reflected in Canadian dollars unless otherwise stated All dollar amounts reflected in Canadian dollars unless otherwise stated...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2025
RKV
LISTED
TSX
Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
News Preview
VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”) announces that in accordance with the terms of an indenture entered into between the Company and Odyssey Trust Company dated May 29, 2023 (the “Indenture”), certain holders (each, a “Debentureholder”) of 1...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.04.2025
RKV
LISTED
TSX
Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update
News Preview
VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery announced the financial results for its fourth quarter and fiscal year ending December 31, 2024 and p...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.04.2025
RKV
LISTED
TSX
Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel
News Preview
VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the appointments of Mr. Yevgeniy Meshcherekov and Dr. David Kideckel to the Compan...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.04.2025
RKV
LISTED
TSX
Rakovina Therapeutics Showcases Preclinical Results of Novel AI-Discovered Cancer Therapies at AACR 2025
News Preview
Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies...
Themefolio
Profiler
Peergroup
© EQS Newswire
02.04.2025
RKV
LISTED
TSX
First Berlin Equity Research GmbH: Rakovina Therapeutics Inc. | Rating: Buy
News Preview
Original-Research: Rakovina Therapeutics Inc. - from First Berlin Equity Research GmbH
02.04.2025 / 15:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to ......
Themefolio
Profiler
Peergroup
© Globe Newswire
30.01.2025
RKV
LISTED
TSX
Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange
News Preview
VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce that its common shares are now listed on the Frankfurt Stock Exchange (FSE) under the ticker symbol...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.01.2025
RKV
LISTED
TSX
Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week
News Preview
VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics, Inc. (TSX: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel DNA-damage response technologies, is pleased to announce its participation in events and meetings being held alongside the 43rd Annual J.P. Morgan Heal...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.12.2024
RKV
LISTED
TSX
Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
News Preview
VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that in accordance with the terms of an indenture entered into between the Company and Odyssey Trust Company (“Odyssey”) dated May 29, 2023 (the “Indenture”), certain holders (each, a “Debentureholder”) of...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.12.2024
RKV
LISTED
TSX
Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement
News Preview
VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”, “Rakovina”, or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the closing of a $3.0 million private placement...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2024
RKV
LISTED
TSX
Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million
News Preview
VANCOUVER, British Columbia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce that its previously announced private placement has been fur...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.11.2024
RKV
LISTED
TSX
Rakovina Therapeutics Announces 2024 Q3 Financial Results and Provides Corporate Update
News Preview
All dollar amounts reflected in Canadian dollars unless otherwise stated All dollar amounts reflected in Canadian dollars unless otherwise stated...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.11.2024
RKV
LISTED
TSX
Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million
News Preview
VANCOUVER, British Columbia, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce that, in response to investor demand, the Company intends to...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.11.2024
RKV
LISTED
TSX
Rakovina Therapeutics Announces Private Placement Offering
News Preview
The Company has received initial commitments totaling over $800,000 from strategic investors in connection with the Offering The Company has received initial commitments totaling over $800,000 from strategic investors in connection with the Offering...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2024
RKV
LISTED
TSX
Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update
News Preview
All dollar amounts reflected in Canadian dollars unless otherwise stated....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.07.2024
RKV
LISTED
TSX
Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement
News Preview
All dollar amounts reflected in Canadian dollars unless otherwise stated. All dollar amounts reflected in Canadian dollars unless otherwise stated....
Themefolio
Profiler
Peergroup
© Globe Newswire
23.07.2024
RKV
LISTED
TSX
Rakovina Therapeutics Provides Update on Previously Announced Private Placement
News Preview
All dollar amounts reflected in Canadian dollars unless otherwise stated....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.07.2024
RKV
LISTED
TSX
Rakovina Therapeutics Announces Second Upsizing of Private Placement
News Preview
All dollar amounts reflected in Canadian dollars unless otherwise stated....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2024
RKV
LISTED
TSX
Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting
News Preview
All dollar amounts reflected in Canadian dollars unless otherwise stated All dollar amounts reflected in Canadian dollars unless otherwise stated...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2024
RKV
LISTED
TSX
Rakovina Therapeutics Announces 2024 Q1 Financial Results and Provides Corporate Update
News Preview
All dollar amounts reflected in Canadian dollars unless otherwise stated All dollar amounts reflected in Canadian dollars unless otherwise stated...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.05.2024
RKV
LISTED
TSX
Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
News Preview
All monetary figures listed in Canadian Dollars....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
